Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Palatin Technologies Inc PTN

Healthcare Biotechnology
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:PTN)

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

PR Newswire April 8, 2024

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

PR Newswire February 28, 2024

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

PR Newswire February 15, 2024

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

PR Newswire February 9, 2024

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

PR Newswire February 5, 2024

Palatin Announces Closing of $10 Million Registered Direct Offering

PR Newswire February 1, 2024

Palatin Announces $10 Million Registered Direct Offering

PR Newswire January 30, 2024

Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024

PR Newswire January 8, 2024

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Business Wire January 3, 2024
View More News ››

Opinion & Analysis (NYSEAM:PTN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSEAM:PTN)

News found December 22, 2020

Here is what I found. https://finance.yahoo.com/news/2-penny-stocks-poised-massive-181758413.html  "...  $3 price...
Bazvest - December 23, 2020

RE:Multiple offers on table

fundtrader u just poped the cherry for this board. Want to add that fact ptn has warrants that will continue to hold the price below 66c...
poorgrammar - November 13, 2016

Multiple offers on table

study is successful. Drug is way better then addyi .( more like a real female viagra) takeover will happen shortly . Multi bagger at...
fundtrader - November 4, 2016

Watch PTN on regular market open up on pre market

CRANBURY, N.J., Aug. 18, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing...
osirus1 - August 19, 2015

Boom...POP...BLAST OFF

http://seekingalpha.com/news/2563446-palatin-plus-28_9-percent-fda-adcomm-recommends-approving-hsdd-drug
Chefboy69 - June 4, 2015

NEWS !!!

With the ageing population it will be worth millions $$$ Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous...
sohappy_4u - August 17, 2010
View more Bullboard ››

IAMGOLD Corp

IAMGOLD Corp

IAMGOLD Corporation is a Canada-based intermediate gold producer and developer. The Company’s principal activities are the ...
View More »